Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID ‐19 pandemic: The real‐world experience of a single center

Abstract

There have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long‐term drug survival data (ie, time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR‐TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36, and 48 weeks, and annually thereafter. The behaviors of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID‐19 pandemic, were also investigated.

Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis

“…Three studies [ 14 , 15 , 16 ] did not show data on persistence or the number of persistent patients, while one did not show data on adherence [ 17 ]; two studies were conducted on patients not only affected by psoriasis [ 18 , 19 ] and did not report adherence data for psoriasis patients; one study [ 20 ] did not report the number of patients treated with each biological drug but only adherence as percentage. Fifty-five studies [ 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , …”

Clinical Dermatology and COVID-19 Pandemic

“…[ 42 ] Such findings have also been extrapolated in pediatric patients suffering from psoriasis who experienced disease flares during a mandatory lockdown and had their medication stopped for COVID-related reasons. [ 43 ] Despite these associations, as well as the excellent safety profile of biological agents in psoriasis patients infected with COVID-19,[ 44 45 46 47 48 49 50 51 ] the rate of biological initiation for psoriasis has decreased during the pandemic. [ 52 ] This, as well as flares in disease, may be explained by diminished access to tertiary dermatology centers responsible for the initiation of biological agents[ 53 ] as well as patients fearing the initiation or continuation of immunosuppressive agents.…”

Management of Children with Psoriasis During the COVID-19 Pandemic

“…Чтобы определить состояние пациентов с псориазом во время пандемии COVID-19, которые находились на терапии этанерцептом, исследователи связались с 57 пациентами по телефону. Опрос показал, что 41 (72%) пациент продолжал лечение без перерыва, 16 (28%) прекратили лечение по нескольким причинам, а именно: продолжение работы и невозможность соблюдения социальной дистанции на рабочем месте (n = 6), опасения по поводу безопасности (n = 5), трудности с доступом к препарату (n = 4) и оперативное вмешательство на сердце (n = 1) [23]. Коронавирусная инфекция была подтверждена методом ПЦР только у одного пациента, контактировавшего с инфицированным человеком.…”

“…Этот пациент не нуждался в госпитализации и выздоровел после лечения дома. За это время пациент прекратил лечение этанерцептом на 1 мес [23].…”